Show simple item record

dc.contributor.authorStannard, Kimberleyen_US
dc.contributor.authorCollins, Patricken_US
dc.contributor.authorIto, Koichien_US
dc.contributor.authorSullivan, Emilyen_US
dc.contributor.authorScott, Stacyen_US
dc.contributor.authorGabutero, Elwynen_US
dc.contributor.authorGrice, Darrenen_US
dc.contributor.authorJ. Nilsson, Ulf.en_US
dc.contributor.authorLeffler, Hakonen_US
dc.contributor.authorBlanchard, Helenen_US
dc.contributor.authorRalph, Stephenen_US
dc.date.accessioned2017-05-03T11:47:35Z
dc.date.available2017-05-03T11:47:35Z
dc.date.issued2010en_US
dc.date.modified2011-03-07T08:52:55Z
dc.identifier.issn03043835en_US
dc.identifier.doi10.1016/j.canlet.2010.08.005en_AU
dc.identifier.urihttp://hdl.handle.net/10072/36847
dc.description.abstractHigh level galectin-1 expression results in cancer cell evasion of the immune response, increased tumour survival and aggressive metastases. Using a galectin-1 polyclonal antibody, high levels of galectin-1 protein were shown to be expressed by breast cancer cells established from FVB/N MMTV-c-neu mice as well as by the B16F10 melanoma cell line. In mixed lymphocyte cultures using tumour cells as antigenic stimulators, addition of recombinant galectin-1 dose-dependently inhibited lymphocyte production. Disaccharides were identified that inhibited galectin-1 function and increased growth and activation of CD8+ CTL's killing cancer cells. X-ray crystallographic structures of human galectin-1 in complex with inhibitory disaccharides revealed their mode of binding. Combining galectin-blocking carbohydrates as adjuvants with vaccine immunotherapy in vivo to promote immune responses significantly decreased tumour progression and improved the outcomes for tumour challenged mice. This is the first report showing that suitably selected galectin-1 blocking disaccharides will act as adjuvants promoting vaccine stimulated immune responses against tumours in vivo.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherElsevieren_US
dc.publisher.placeIrelanden_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom95en_US
dc.relation.ispartofpageto110en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalCancer Lettersen_US
dc.relation.ispartofvolume299en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchOncology and Carcinogenesis not elsewhere classifieden_US
dc.subject.fieldofresearchcode111299en_US
dc.titleGalectin inhibitory disaccharides promote tumour immunity in a breast cancer modelen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medicineen_US
gro.date.issued2010
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record